{"id":266798,"date":"2025-12-23T00:00:00","date_gmt":"2025-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/?post_type=report&#038;p=265353"},"modified":"2026-03-31T10:23:42","modified_gmt":"2026-03-31T10:23:42","slug":"algoim0050-2025-biopharma-alopecia-current-treatment-treatment-algorithms-claims-data-analysis-alopecia-areata-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0050-2025-biopharma-alopecia-current-treatment-treatment-algorithms-claims-data-analysis-alopecia-areata-us\/","title":{"rendered":"Alopecia &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Alopecia Areata (US)"},"content":{"rendered":"<p>Alopecia areata (<abbr title=\"alopecia areata\">AA<\/abbr>) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical \/ intralesional corticosteroids have historically dominated prescription treatment for <abbr title=\"alopecia areata\">AA<\/abbr>. However, beginning in 2022, several therapies, all part of the <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitor family, have gained <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for the treatment of severe <abbr title=\"alopecia areata\">AA<\/abbr>: Eli Lilly\u2019s Olumiant (baricitinib), Pfizer\u2019s Litfulo (ritlecitinib), and Sun Pharma\u2019s Leqselvi (deuruxolitinib [commercially available as of mid-2025]). With the <abbr title=\"alopecia areata\">AA<\/abbr> treatment landscape continuing to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices in <abbr title=\"alopecia areata\">AA<\/abbr> and to define the market niche for emerging products.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"alopecia areata\">AA<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"alopecia areata\">AA<\/abbr> patients?<\/li>\n<li>How have Olumiant and Litfulo been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"alopecia areata\">AA<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"alopecia areata\">AA<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis<em> <\/em>provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key drugs:<\/strong> Corticosteroids (injectable, oral, topical), minoxidil, finasteride, dutasteride, Litfulo, Olumiant<\/p>\n<p><b>Key features: <\/b>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Produce enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-266798","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/266798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/266798\/revisions"}],"predecessor-version":[{"id":575230,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/266798\/revisions\/575230"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=266798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}